Smythe MA, Mattson JC, Koerber JM (2002) The heparin anti- Xa therapeutic range: are we there yet? Chest 121:303-304Smythe MA, Mattson JC. The heparin anti-Xa therapeutic range. Are we there yet? Chest 2002;121:303.Smythe MA, Koerber JL, Mattson JC. The heparin anti-Xa therapeutic ...
To describe the successful use of high-dose enoxaparin therapy (1.5 mg/kg subcutaneously twice daily) to attain a therapeutic anti-factor Xa (anti-Xa) level in a cancer patient with heparin resistance.A proven heparin-resistant patient with venous thromboembolism (VTE) and lung cancer who require...
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate? Anti-Factor Xa (Anti-Xa) assays specifically determine the anticoagulant activity of UFH by measuring the ability of heparin-bound Antithrombin (AT) to inh... V Ignjatovic,R Summerhayes,A Gan,... - 《...
Changing a heparin order set to utilize anti Xa monitoring and to improve time to therapeutic anticoagulationMoyers, PTatro, JFerguson, TBall, JTimmons, C
英文名:Injection Heparinum Natricum Minor Molecularis汉语拼音:Difenzi Gansuna Zhusheye主要成分:性状:无色澄明液体。药理作用:具有持久的抗血栓形成作用,是预防和治疗血栓栓塞性疾病的新药。经家兔静脉给药后,七种凝血指标测定体外抗血栓试验和大鼠体内三种抗血栓形成试验,表明吉派啉具有抗凝、抗血栓形成作用,与肝素...
60, and the other investigated rivaroxaban, which is a factor Xa inhibitor61(whereas other RCTs evaluated the use of unfractionated or low-molecular-weight heparin (LMWH)). Finally, patients at high risk of VTE might benefit from post-discharge pharmacological thromboprophylaxis62,63, which also ...
NOVEL ANTI-CANCER THERAPEUTIC COMPOUNDS FIELD OF THE INVENTION The present invention is of therapeutic compounds for cancer, and in particular, of therapeutic compounds which block the ability of cytokines and chemokines to promote metastasis of malignant cells, and which are heparin and heparan-sulfate...
Anti-Xa agents In general, anti-Xa agents are classified into heparin-related products and direct thrombin inhibitors. Heparin is a naturally occurring polysaccharide. It can activate the enzyme inhibitor antithrombin III (AT) by inducing a conformational change. The heparin-activated AT then inactiva...
We recommend measuring anti-activated factor X (anti-Xa) activity—calibrated to low molecular weight heparin (LMWH) or the specific “xaban” of interest—to rule out apixaban, edoxaban, or rivaroxaban anticoagulation. (a) Calibrated to LMWH, an anti-Xa activity below the detection limit of th...
(C5) activation products, C5a and C5b-9 in the patients with COVID-19 indicated complement activation.141S protein of SARS-CoV-2 can interfere with the function of complement factor H to activate complement bypass, and directly block the combination of complement factor H with heparin, ...